New Oakland Child-Adolescent and Family Center
New Oakland offers a Pharmaceutical Research Treatment Line. The goal of this program is to integrate New Oakland's System of Care and the skills of New Oakland's psychiatrists and clinicians with the country's leading pharmaceutical companies. New Oakland's division of Pharmaceutical Research is under the leadership of the Company's Executive Medical Director, Ismail B. Sendi, MD, MS, in conjunction with Kimberly Smith, LMSW, CCRC.
New Oakland is currently participating in several research projects with leading pharmaceutical companies that have contracted with management to study the efficacy of approved psychiatric medications. In addition to working with New Oakland outpatient, FACE to FACE Intensive Outpatient and FACE to FACE Partial Hospital Day Program treatment models at all facilities, New Oakland Pharmaceutical Research may also contract with additional behavioral healthcare providers regionally. There is a growing need for high quality pharmaceutical research studies as evidenced by New Oakland being approached frequently to provide sites for psycho-pharmaceutical research.